Your session is about to expire
← Back to Search
Letrozole for Endometrial Adenocarcinoma
Study Summary
This trial is studying how well abemaciclib and letrozole work in treating patients with endometrial cancer.
- Endometrial Endometrioid Adenocarcinoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 4 trial • 79 Patients • NCT02137538Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many participants are allowed to register for this research project?
"Affirmative. The information on clinicaltrials.gov demonstrates that this research is presently recruiting candidates. This investigation, which was initiated on August 12th 2019, needs 27 participants from two sites to be enrolled."
Has recruitment for this experiment begun?
"This clinical trial remains open for recruitment, as per the information on clinicaltrials.gov. This medical study was initially posted to the platform on August 12th 2019 and had its most recent update April 30th 2021."
Has Letrozole been studied and analyzed in other scientific experiments?
"Currently, there are 228 clinical trials for Letrozole that have been initiated. Of these studies, 50 are in Phase 3. San Francisco is the most popular location conducting research into this treatment but other sites across America also exist - 15288 to be exact."
In which medical cases is Letrozole generally utilized?
"Letrozole is a frequently prescribed therapy for treating breast cancer, but it has also been effectively used to manage anovulatory cycle and tamoxifen-resistant conditions."
Share this study with friends
Copy Link
Messenger